

**Experiment Number:** 88149-02  
**Test Type:** 14-DAY  
**Route:** GAVAGE  
**Species/Strain:** Mouse/B6C3F1

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)**

**Test Compound:** 3,3',4,4'-Tetrachloroazoxybenzene

**CAS Number:** 21232-47-3

**Date Report Requested:** 10/21/2014

**Time Report Requested:** 18:24:40

**First Dose M/F:** NA / NA

**Lab:** MBA

<b>C Number:</b>	C88149
<b>Lock Date:</b>	01/19/1994
<b>Cage Range:</b>	All
<b>Date Range:</b>	All
<b>Reasons For Removal:</b>	All
<b>Removal Date Range:</b>	All
<b>Treatment Groups:</b>	All
<b>Study Gender:</b>	Both
<b>PWG Approval Date</b>	NONE

Experiment Number: 88149-02  
 Test Type: 14-DAY  
 Route: GAVAGE  
 Species/Strain: Mouse/B6C3F1

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)**  
 Test Compound: 3,3',4,4'-Tetrachloroazoxybenzene  
 CAS Number: 21232-47-3

Date Report Requested: 10/21/2014  
 Time Report Requested: 18:24:40  
 First Dose M/F: NA / NA  
 Lab: MBA

B6C3F1 Mouse MALE	0 MG/KG	1 MG/KG	3.2 MG/KG	10 MG/KG	32 MG/KG	100 MG/KG
<b>Disposition Summary</b>						
Animals Initially In Study	5	5	5	5	5	5
Early Deaths						
Survivors						
Terminal Sacrifice	5	5	5	5	5	5
Animals Examined Microscopically	5	5	5	5	5	5
<b>ALIMENTARY SYSTEM</b>						
Esophagus	(0)	(0)	(0)	(0)	(0)	(1)
Cyst						1 (100%)
Gallbladder	(5)	(0)	(0)	(0)	(0)	(5)
Liver	(5)	(5)	(5)	(5)	(5)	(5)
Hepatocyte, Inflammation, Focal	2 (40%)	2 (40%)	3 (60%)	2 (40%)	2 (40%)	5 (100%)
Hepatocyte, Necrosis, Focal	1 (20%)	1 (20%)	2 (40%)	2 (40%)	1 (20%)	5 (100%)
Stomach, Forestomach	(5)	(0)	(0)	(0)	(0)	(5)
Stomach, Glandular	(5)	(0)	(0)	(0)	(0)	(5)
<b>CARDIOVASCULAR SYSTEM</b>						
None						
<b>ENDOCRINE SYSTEM</b>						
None						
<b>GENERAL BODY SYSTEM</b>						
None						
<b>GENITAL SYSTEM</b>						
None						
<b>HEMATOPOIETIC SYSTEM</b>						
Lymph Node, Mesenteric	(5)	(0)	(0)	(0)	(0)	(5)
Spleen	(5)	(5)	(5)	(5)	(5)	(5)
Red Pulp, Hematopoietic Cell Proliferation	1 (20%)	4 (80%)	2 (40%)	3 (60%)	2 (40%)	5 (100%)

a - Number of animals examined microscopically at site and number of animals with lesion

**Experiment Number:** 88149-02  
**Test Type:** 14-DAY  
**Route:** GAVAGE  
**Species/Strain:** Mouse/B6C3F1

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)**  
**Test Compound:** 3,3',4,4'-Tetrachloroazoxybenzene  
**CAS Number:** 21232-47-3

**Date Report Requested:** 10/21/2014  
**Time Report Requested:** 18:24:40  
**First Dose M/F:** NA / NA  
**Lab:** MBA

<b>B6C3F1 Mouse MALE</b>	<b>0 MG/KG</b>	<b>1 MG/KG</b>	<b>3.2 MG/KG</b>	<b>10 MG/KG</b>	<b>32 MG/KG</b>	<b>100 MG/KG</b>
Red Pulp, Pigmentation				1 (20%)		
Thymus Atrophy	(5)	(4)	(5)	(5)	(5)	(5)
Thymocyte, Atrophy, Diffuse					1 (20%)	5 (100%)
<b>INTEGUMENTARY SYSTEM</b>						
None						
<b>MUSCULOSKELETAL SYSTEM</b>						
None						
<b>NERVOUS SYSTEM</b>						
None						
<b>RESPIRATORY SYSTEM</b>						
None						
<b>SPECIAL SENSES SYSTEM</b>						
None						
<b>URINARY SYSTEM</b>						
Kidney	(5)	(0)	(0)	(0)	(0)	(5)

\*\*\*END OF MALE DATA\*\*\*

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 88149-02

Test Type: 14-DAY

Route: GAVAGE

Species/Strain: Mouse/B6C3F1

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)**

Test Compound: 3,3',4,4'-Tetrachloroazoxybenzene

CAS Number: 21232-47-3

Date Report Requested: 10/21/2014

Time Report Requested: 18:24:40

First Dose M/F: NA / NA

Lab: MBA

B6C3F1 Mouse FEMALE	0 MG/KG	1 MG/KG	3.2 MG/KG	10 MG/KG	32 MG/KG	100 MG/KG
<b>Disposition Summary</b>						
Animals Initially In Study	5	5	5	5	5	5
Early Deaths						
Survivors						
Terminal Sacrifice	5	5	5	5	5	5
Animals Examined Microscopically	5	5	5	5	5	5
<b>ALIMENTARY SYSTEM</b>						
Gallbladder	(5)	(0)	(0)	(0)	(0)	(5)
Liver	(5)	(5)	(5)	(5)	(5)	(5)
Hepatocyte, Inflammation, Focal	4 (80%)	3 (60%)	4 (80%)	4 (80%)	5 (100%)	5 (100%)
Hepatocyte, Necrosis, Focal	1 (20%)	3 (60%)	4 (80%)	3 (60%)	2 (40%)	5 (100%)
Stomach, Forestomach	(5)	(0)	(0)	(0)	(0)	(5)
Stomach, Glandular	(5)	(0)	(0)	(0)	(0)	(5)
<b>CARDIOVASCULAR SYSTEM</b>						
None						
<b>ENDOCRINE SYSTEM</b>						
None						
<b>GENERAL BODY SYSTEM</b>						
None						
<b>GENITAL SYSTEM</b>						
None						
<b>HEMATOPOIETIC SYSTEM</b>						
Lymph Node, Mesenteric	(5)	(0)	(0)	(0)	(0)	(5)
Spleen	(5)	(5)	(5)	(5)	(5)	(5)
Red Pulp, Hematopoietic Cell Proliferation	3 (60%)	4 (80%)	5 (100%)	5 (100%)	2 (40%)	5 (100%)
Thymus	(5)	(4)	(5)	(5)	(5)	(5)
Thymocyte, Atrophy, Diffuse						2 (40%)

a - Number of animals examined microscopically at site and number of animals with lesion

**Experiment Number:** 88149-02  
**Test Type:** 14-DAY  
**Route:** GAVAGE  
**Species/Strain:** Mouse/B6C3F1

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)**  
**Test Compound:** 3,3',4,4'-Tetrachloroazoxybenzene  
**CAS Number:** 21232-47-3

**Date Report Requested:** 10/21/2014  
**Time Report Requested:** 18:24:40  
**First Dose M/F:** NA / NA  
**Lab:** MBA

<b>B6C3F1 Mouse FEMALE</b>	<b>0 MG/KG</b>	<b>1 MG/KG</b>	<b>3.2 MG/KG</b>	<b>10 MG/KG</b>	<b>32 MG/KG</b>	<b>100 MG/KG</b>
INTEGUMENTARY SYSTEM None						
MUSCULOSKELETAL SYSTEM None						
NERVOUS SYSTEM None						
RESPIRATORY SYSTEM None						
SPECIAL SENSES SYSTEM None						
URINARY SYSTEM Kidney Cortex, Inflammation, Focal	(5)	(0)	(0)	(0)	(0)	(5) 1 (20%)

**\*\* END OF REPORT \*\***